Prevention of indomethacin-induced intestinal ulcers by spironolactone and norbolethone.
D045930:Anabolic Agents / Q000627:therapeutic use*; D000818:Animals; D004064:Digestive System / Q000473:pathology; D005260:Female; D007213:Indomethacin; D010437:Peptic Ulcer / Q000139:chemically induced / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D010538:Peritonitis / Q000517:prevention & control; D051381:Rats; D013148:Spironolactone / Q000627:therapeutic use*
D045930:Anabolic Agents; D013148:Spironolactone; D007213:Indomethacin